Trial Profile

A Phase 0 Master Protocol Using the CIVO Platform to Evaluate Intratumoural Microdoses of Anti-Cancer Therapies in Patients With Solid Tumours

Status: Withdrawn prior to enrolment

Phase of Trial: Phase 0

Latest Information Update: 11 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; TAK 186 (Primary)
Indications Solid tumours
Focus Biomarker; Pharmacodynamics
Sponsors Presage Biosciences

Most Recent Events

05 Jul 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
22 Sep 2021 Planned initiation date changed from 1 Jul 2021 to 1 Oct 2021.
21 May 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com